Plasma Levels of MMP-7 and TIMP-1 in Laboratory Diagnostics and Differentiation of Selected Histological Types of Epithelial Ovarian Cancers

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2017 Jul 1

PMID 28662671

Citations 12

Authors

Grazyna Ewa Bedkowska

Ewa Gacuta

Monika Zajkowska

Edyta Katarzyna Glazewska

Joanna Osada

Maciej Szmitkowski

Lech Chrostek

Milena Dabrowska

Slawomir Lawicki

Affiliations

Soon will be listed here.

Abstract

Background: MMP-7 and TIMP-1 may play a role in the pathogenesis of cancer disease. In this study we investigated plasma levels of selected metalloproteinase and its tissue inhibitor in comparison to plasma levels of the commonly accepted tumor markers (CA 125 and HE4) in selected histological types of epithelial ovarian cancer patients as compared to control groups: patients with a benign ovarian tumor and healthy subjects. Plasma levels of MMP-7 and TIMP-1 were determined using ELISA, CA 125 and HE4 - by CMIA methods.

Results: Plasma levels of all biomarkers studied were significantly higher in ovarian cancer patients as compared to both control groups. MMP-7 demonstrated comparable to HE4 or CA125 values of diagnostic sensitivity (SE: 61%; 68%; 58%, respectively), specificity (SP: 95%; 95%; 98%, respectively), positive (PPV: 93%; 96%; 98%, respectively) and negative predictive values (NPV: 61%; 66%; 60%, respectively) in the groups tested. The combined use of the aforementioned biomarkers resulted in a further increase in diagnostic criteria and AUC, especially in the early stages of the disease.

Conclusions: These findings suggest the usefulness of combining MMP-7 with CA 125 and HE4 in the diagnosis of epithelial ovarian cancer as a new tumor marker panel.

Citing Articles

Diagnostic Utility of Metalloproteinases from Collagenase Group (MMP-1, MMP-8 and MMP-13) in Biochemical Diagnosis of Ovarian Carcinoma.

Kicman A, Gacuta E, Marecki R, Kicman M, Kulesza M, Klank-Sokolowska E Cancers (Basel). 2024; 16(23).

PMID: 39682156 PMC: 11640008. DOI: 10.3390/cancers16233969.

Diagnostic Utility of Selected Matrix Metalloproteinases (MMP-2, MMP-3, MMP-11, MMP-26), HE4, CA125 and ROMA Algorithm in Diagnosis of Ovarian Cancer.

Kicman A, Gacuta E, Kulesza M, Bedkowska E, Marecki R, Klank-Sokolowska E Int J Mol Sci. 2024; 25(11).

PMID: 38892452 PMC: 11173327. DOI: 10.3390/ijms25116265.

Redox Biomarkers and Matrix Remodeling Molecules in Ovarian Cancer.

Supruniuk E, Baczewska M, Zebrowska E, Maciejczyk M, Lauko K, Dajnowicz-Brzezik P Antioxidants (Basel). 2024; 13(2).

PMID: 38397798 PMC: 10885995. DOI: 10.3390/antiox13020200.

Quantification of putative ovarian cancer serum protein biomarkers using a multiplexed targeted mass spectrometry assay.

Ryu J, Boylan K, Twigg C, Evans R, Skubitz A, Thomas S Clin Proteomics. 2024; 21(1):1.

PMID: 38172678 PMC: 10762856. DOI: 10.1186/s12014-023-09447-4.

Plasma Levels of Metalloproteinase 3 (MMP-3) and Metalloproteinase 7 (MMP-7) as New Candidates for Tumor Biomarkers in Diagnostic of Breast Cancer Patients.

Lawicki P, Malinowski P, Motyka J, Lawicki M, Kicman A, Kulesza M J Clin Med. 2023; 12(7).

PMID: 37048701 PMC: 10094779. DOI: 10.3390/jcm12072618.

References

Stamenkovic I . Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003; 200(4):448-64. DOI: 10.1002/path.1400. View

Lawicki S, Bedkowska G, Gacuta-Szumarska E, Szmitkowski M . Hematopoietic cytokines as tumor markers in gynecological malignancies: a multivariate analysis with ROC curve in endometrial cancer patients. Growth Factors. 2011; 30(1):29-36. DOI: 10.3109/08977194.2011.627332. View

Koskensalo S, Mrena J, Wiksten J, Nordling S, Kokkola A, Hagstrom J . MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 2010; 31(3):149-55. DOI: 10.1007/s13277-010-0020-1. View

Gong Y, Chippada-Venkata U, Galsky M, Huang J, Oh W . Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. Prostate. 2015; 75(6):616-27. DOI: 10.1002/pros.22945. View

Wu Z, Wu Q, Yang J, Wang H, Ding X, Yang F . Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008; 122(9):2050-6. DOI: 10.1002/ijc.23337. View

Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C . HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta. 2011; 412(15-16):1447-53. DOI: 10.1016/j.cca.2011.04.028. View

Zohny S, Fayed S . Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol. 2009; 27(4):1246-53. DOI: 10.1007/s12032-009-9366-x. View

Lawicki S, Bedkowska G, Gacuta-Szumarska E, Knapp P, Szmitkowski M . Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients. Folia Histochem Cytobiol. 2012; 50(2):213-9. DOI: 10.5603/fhc.2012.0030. View

Xiao X, Lang X . Correlation Between MMP-7 and bFGF Expressions in Non-small Cell Lung Cancer Tissue and Clinicopathologic Features. Cell Biochem Biophys. 2016; 73(2):427-432. DOI: 10.1007/s12013-015-0656-y. View

10.

Azzam A, Hashad D, Kamel N . Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?. Arch Gynecol Obstet. 2013; 288(1):167-72. DOI: 10.1007/s00404-013-2722-2. View

11.

Galgano M, Hampton G, Frierson Jr H . Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19(6):847-53. DOI: 10.1038/modpathol.3800612. View

12.

Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I . Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2011; 125(1):65-9. PMC: 3303992. DOI: 10.1016/j.ygyno.2011.11.050. View

13.

Lawicki S, Bedkowska G, Gacuta-Szumarska E, Szmitkowski M . The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res. 2013; 6(1):45. PMC: 3706238. DOI: 10.1186/1757-2215-6-45. View

14.

Worley J, Thompkins P, Lee M, Hutton M, Soloway P, Edwards D . Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochem J. 2003; 372(Pt 3):799-809. PMC: 1223438. DOI: 10.1042/BJ20021573. View

15.

Holten-Andersen L, Christensen I, Jensen S, Reibel J, Laurberg S, Nauntofte B . Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study. Scand J Gastroenterol. 2012; 47(10):1234-41. DOI: 10.3109/00365521.2012.711855. View

16.

Drapkin R, von Horsten H, Lin Y, C Mok S, Crum C, Welch W . Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65(6):2162-9. DOI: 10.1158/0008-5472.CAN-04-3924. View

17.

Vergote I, Banerjee S, Gerdes A, van Asperen C, Marth C, Vaz F . Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer. 2016; 69:127-134. DOI: 10.1016/j.ejca.2016.10.006. View

18.

Niedworok C, Vom Dorp F, Tschirdewahn S, Rubben H, Reis H, Szucs M . Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method. Int Urol Nephrol. 2016; 48(3):355-61. DOI: 10.1007/s11255-015-1185-8. View

19.

Lawicki S, Gacuta-Szumarska E, Bedkowska G, Szmitkowski M . Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients. Growth Factors. 2012; 30(6):357-66. DOI: 10.3109/08977194.2012.724407. View

20.

Kren L, Goncharuk V, Krenova Z, Stratil D, Hermanova M, Skrickova J . Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. Cesk Patol. 2006; 42(1):16-9. View